Press Releases April 22, 2026 07:45 PM

Rogers Communications Announces Voting Results from Annual General Meeting of Shareholders

Rogers Communications Announces Completion of Annual General Meeting with Full Support for Directors and Auditors

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
RCI

Rogers Communications Inc. reported the voting results from its Annual General Meeting held on April 22, 2026. Shareholders overwhelmingly approved all items on the agenda, including the election of all nominated directors and appointment of KPMG LLP as auditors. Approximately 97.65% of Class A voting shares were represented in the vote.

Rogers Communications Announces Voting Results from Annual General Meeting of Shareholders
RCI
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • All director nominees were elected with over 99.9% shareholder approval.
  • KPMG LLP was reappointed as auditors with nearly unanimous shareholder support.
  • High shareholder turnout with more than 97% of Class A Voting shares represented.
  • Impacted sectors include telecommunications, entertainment, and investment markets due to Rogers' business scope.

TORONTO, April 22, 2026 (GLOBE NEWSWIRE) -- Rogers Communications Inc. (TSX: RCI.A and RCI.B) (NYSE: RCI) (the “Company”), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual General Meeting of Shareholders held earlier today.

Shareholders voted for all items of business put forth at today’s meeting, those being the election of the director nominees and the appointment of KPMG LLP as the Company’s auditors. A total of 108,537,470 Class A Voting shares, representing approximately 97.65% of the Company's issued and outstanding Class A Voting shares, were voted in connection with the election of directors.

Director NomineeResult% of Shares
Voted For% of Shares
Voted WithholdMichael J. CooperElected99.982%0.018%Trevor EnglishElected99.993%0.007%Ivan FecanElected99.991%0.009%Robert J. GemmellElected99.992%0.008%Jan L. InnesElected99.993%0.007%Diane A. KazarianElected99.997%0.003%Dr. Mohamed LachemiElected99.991%0.009%David A. RobinsonElected99.993%0.007%Edward S. RogersElected99.984%0.016%Lisa A. RogersElected99.994%0.006%Bradley S. ShawElected99.992%0.008%Wayne SparrowElected99.993%0.007%Tony StaffieriElected99.991%0.009%John H. ToryElected99.992%0.008%


A total of 108,567,017 Class A Voting shares, representing approximately 97.68% of the Company's issued and outstanding Class A Voting shares, were voted in connection with the appointment of auditors.

AuditorsResult% of Shares
Voted For% of Shares
Voted WithholdKPMG LLPAppointed99.998%0.002%


For director biographies, please visit https://about.rogers.com/our-story/board-of-directors/.

About Rogers Communications Inc:
Rogers is Canada’s communications, sports and entertainment company and its shares are publicly traded on the Toronto Stock Exchange (TSX: RCI.A and RCI.B) and on the New York Stock Exchange (NYSE: RCI). For more information, please visit rogers.com or about.rogers.com/investor-relations.

For further information:
Investor Relations
1-844-801-4792
[email protected]


Risks

  • The company is subject to governance risks if future shareholder consensus changes.
  • Market conditions and regulatory changes in telecommunications could affect the company despite good governance support.
  • Potential operational risks exist which are not directly addressed by AGM outcomes but could influence future financial performance.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026